Monil Shah

A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC).

Alexis Weston, Monil Shah, R. Stanley Williams, Trason Thode et autres

us (code pays fourni par la source)

Abstract CT240: A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC)

Alexis Weston, Monil Shah, R. Stanley Williams, Trason Thode et autres

688 A phase 1 multi-center, open-label, dose escalation study to evaluate the safety and pharmacokinetics of oral SR-8541A, an ENPP1 inhibitor, in patients with advanced solid tumors

Alexis Weston, Trason Thode, Monil Shah, R. Stanley Williams et autres

us (code pays fourni par la source)

Abstract CT161: First-in-human study of ENPP1 inhibitor, SR-8541A, for the treatment of solid tumors

Alexis Weston, Trason Thode, Monil Shah, Amanda Seiz et autres

us (code pays fourni par la source)

897-G SR-8541A, a small molecule inhibitor of ENPP1, enhances the effect of immune checkpoint inhibitors in a colorectal cancer model

Alexis Weston, Trason Thode, Serina Ng, Tithi Ghosh-Halder et autres

us (code pays fourni par la source)

154 Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors

Eric R. Lutz, Lakshmi Rudraraju, Elizabeth DeOliveira, Amanda Seiz et autres

us (code pays fourni par la source)

Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

Katherine Sanchez, Shu‐Ching Chang, Isaac Kim, Maritza Martel et autres

us (code pays fourni par la source)

Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).

Martin J. Edelman, Aaron Lisberg, Marianna Koczywas, Ben Creelan et autres

us (code pays fourni par la source)

A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

David B. Page, Joanna Pucilowska, Katherine Sanchez, Valerie Conrad et autres

us (code pays fourni par la source)

IRX-2 therapy with PD-L1 blockade in immunocompetent animal model.

Lu Wen, Gregory T. Wolf, Monil Shah, David B. Page et autres

us (code pays fourni par la source)

Evaluation of immunotherapy (I-O)-associated immune cell (IC) dynamics and PD-L1 expression using multispectral immunohistochemistry (mIHC) and single-cell hierarchical regression modeling in early-stage breast cancer (ESBC).

Katherine Sanchez, Maritza Martel, Shu-Ching Chang, Yaping Wu et autres

us (code pays fourni par la source)

Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma

Joanna Pucilowska, Venkatesh Rajamanickam, Nikki Moxon, Monil Shah et autres